Global pharmaceutical company Boehringer Ingelheim is continuing to expand its presence in the animal health sector through a combination of innovative product launches, artificial intelligence-powered veterinary technologies and rapid responses to emerging animal disease outbreaks.
The company’s Animal Health business generated €2.6 billion in net sales during the first half of 2026, representing a 0.4% operational increase compared with the same period last year. While market growth remained modest, Boehringer Ingelheim continued investing in innovation across companion animals, livestock and equine health, reinforcing its long-term strategy of delivering advanced solutions for veterinarians and animal producers.
Animal Health Market Faces Consumer Spending Pressure
Boehringer Ingelheim said market conditions during the first six months of 2026 remained challenging. Increased consumer price sensitivity and a decline in veterinary clinic visits in several countries affected overall market growth, particularly in the companion animal segment.
Despite these headwinds, the company continued executing its global product launch strategy while maintaining investments in research and development.
LENZELTA® Brings New Approach to Mastitis Prevention
One of the company’s most significant launches this year is LENZELTA®, a new vaccine designed to help prevent mastitis in dairy cows.
Mastitis is one of the most costly diseases affecting dairy farming worldwide, reducing milk production, increasing veterinary treatment costs and impacting overall herd health. By helping protect cows against mastitis, LENZELTA aims to improve animal welfare while supporting farm productivity and sustainability.
The vaccine has already been introduced in several European Union countries as part of Boehringer Ingelheim’s expanding dairy health portfolio.
Industry experts believe innovations that reduce disease incidence can also contribute to more responsible antibiotic use by lowering the number of clinical infections requiring treatment.
Artificial Intelligence Enters Veterinary Cardiology
Boehringer Ingelheim has also expanded its digital animal health portfolio with Eko Vet+™ | CANINEBEAT® AI, an artificial intelligence-based diagnostic tool that assists veterinarians in detecting heart murmurs in dogs.
The technology combines digital stethoscope recordings with AI algorithms to support earlier identification of cardiac abnormalities during routine veterinary examinations.
The solution has already launched in the United States, the United Kingdom and Germany, reflecting growing adoption of AI-powered diagnostic technologies in companion animal medicine.
Earlier detection of heart disease can enable veterinarians to perform additional diagnostic testing sooner, potentially improving treatment decisions and long-term patient outcomes.
Supporting the Fight Against New World Screwworm
Beyond commercial product launches, Boehringer Ingelheim continues to support efforts to control emerging livestock diseases.
The company has been involved in the response to the New World screwworm situation in the United States after receiving Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) earlier this year.
New World screwworm is a parasitic fly whose larvae feed on living tissue, posing a serious threat to cattle, horses, sheep, goats, wildlife and other warm-blooded animals. Rapid diagnosis and effective treatment are essential to limit animal suffering and prevent economic losses in affected regions.
The FDA’s emergency authorization enables faster access to products needed during disease response efforts while supporting livestock producers and veterinary professionals managing outbreaks.
Research Pipeline Remains Strong Across Multiple Species
Innovation remains a key pillar of Boehringer Ingelheim’s long-term Animal Health strategy. The company reported continued progress across its research and development pipeline, with multiple candidates advancing in areas including:
-
Infectious diseases
-
Non-infectious diseases
-
Parasiticides
-
Companion animal health
-
Equine medicine
-
Livestock healthcare
By maintaining a broad pipeline across several therapeutic areas, Boehringer Ingelheim aims to address both existing veterinary challenges and emerging health threats affecting pets and food-producing animals.
Why Innovation Matters More Than Ever
The global animal health industry is undergoing rapid transformation. Livestock producers are seeking solutions that improve herd health while supporting sustainable production, while pet owners increasingly expect advanced diagnostic technologies similar to those available in human healthcare.
At the same time, emerging infectious diseases continue to threaten global food security, animal welfare and international trade.
Against this backdrop, investments in vaccines, digital diagnostics, parasiticides and novel therapeutics are becoming increasingly important for maintaining healthy animal populations and improving veterinary care.
Industry Outlook
Although the animal health market experienced slower growth during the first half of 2026, Boehringer Ingelheim’s continued investment in innovation demonstrates confidence in the sector’s long-term prospects.
New vaccines such as LENZELTA®, AI-assisted diagnostic platforms like Eko Vet+™ | CANINEBEAT® AI, and a strong research pipeline position the company to address some of the industry’s most pressing challenges, including disease prevention, early diagnosis and emerging animal health threats.
As veterinary medicine continues to embrace digital technologies and precision healthcare, companies capable of combining scientific innovation with practical solutions for veterinarians and livestock producers are expected to play a leading role in shaping the future of global animal health.
Key Highlights Q2′ 2026 Revenues
-
Animal Health sales reached €2.6 billion in H1 2026.
-
LENZELTA® launched in several European countries to help prevent mastitis in dairy cows.
-
Eko Vet+™ | CANINEBEAT® AI expanded into the U.S., UK and Germany to support early detection of heart murmurs in dogs.
-
Boehringer Ingelheim supported the U.S. response to New World screwworm following FDA Emergency Use Authorizations.
-
The company continues advancing a broad R&D pipeline covering infectious diseases, parasiticides, companion animals, equine health and livestock medicine.
-
Innovation in vaccines, AI diagnostics and disease preparedness remains central to the company’s long-term Animal Health strategy.
